TSBX has 36-month beta value of 2.24. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TSBX is 13.65M, and currently, short sellers hold a 2.84% ratio of that float. The average trading volume of TSBX on November 01, 2024 was 276.53K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TSBX) stock’s latest price update
The stock of Turnstone Biologics Corp (NASDAQ: TSBX) has decreased by -4.01 when compared to last closing price of 0.47. Despite this, the company has experienced a -11.17% fall in its stock price over the last five trading sessions. benzinga.com reported 2024-08-15 that Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday.
TSBX’s Market Performance
Turnstone Biologics Corp (TSBX) has seen a -11.17% fall in stock performance for the week, with a -4.19% decline in the past month and a -80.64% plunge in the past quarter. The volatility ratio for the week is 7.33%, and the volatility levels for the past 30 days are at 7.37% for TSBX. The simple moving average for the past 20 days is -6.08% for TSBX’s stock, with a -79.19% simple moving average for the past 200 days.
Analysts’ Opinion of TSBX
Piper Sandler gave a rating of “Overweight” to TSBX, setting the target price at $20 in the report published on August 15th of the previous year.
TSBX Trading at -20.44% from the 50-Day Moving Average
After a stumble in the market that brought TSBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.09% of loss for the given period.
Volatility was left at 7.37%, however, over the last 30 days, the volatility rate increased by 7.33%, as shares surge +2.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.85% lower at present.
During the last 5 trading sessions, TSBX fell by -10.19%, which changed the moving average for the period of 200-days by -76.04% in comparison to the 20-day moving average, which settled at $0.4848. In addition, Turnstone Biologics Corp saw -82.12% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TSBX
The total capital return value is set at -1.3. Equity return is now at value -134.46, with -98.52 for asset returns.
Based on Turnstone Biologics Corp (TSBX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -30.75.
Currently, EBITDA for the company is -56.23 million with net debt to EBITDA at 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.38.
Conclusion
To put it simply, Turnstone Biologics Corp (TSBX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
